Copyright
©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. Nov 6, 2017; 8(4): 193-200
Published online Nov 6, 2017. doi: 10.4292/wjgpt.v8.i4.193
Published online Nov 6, 2017. doi: 10.4292/wjgpt.v8.i4.193
Characteristics | Responders | Partial responders | Primarily non-responders |
n (%) | 72 (67.29) | 22 (21.57) | 13 (14.74) |
Age (yr, mean ± SD) | 34.10±11.63 | 32.23 ± 13.31 | 39.09 ± 15.60 |
Sex (%) | |||
Male | 30 (41.67) | 14 (63.64) | 10 (76.92) |
Female | 42 (62.69) | 8 (36.36) | 3 (23.08) |
C-reactive protein (mg/dL, mean ± SD) | |||
Baseline | 3.10 ± 2.03 | 4.13 ± 2.31 | 6.86 ± 2.89 |
After treatment | 0.88 ± 1.84 | 2.21 ± 2.69 | 3.96 ± 2.81 |
δC-reactive protein (%) | 80.44 ± 22.42 | 71.94 ± 45.74 | 58.04 ± 22.63 |
Duration of disease (yr) | 6.38 ± 5.91 | 5.71 ± 3.77 | 4.00 ± 3.13 |
Infliximab dose (mg/kg) | 5 | 5 | 5 |
Location | |||
L2 | 24 (33.34) | 3 (13.64) | 2 (15.38) |
L3 | 45 (62.50) | 19 (86.36) | 11 (84.62) |
L4 | 3 (4.48) | 0 | 0 |
Behavior | |||
B1 | 31 (43.06) | 7 (31.82) | 5 (38.46) |
B2 | 13 (18.06) | 6 (27.27) | 2 (15.38) |
B3 | 28 (38.89) | 9 (40.91) | 6 (46.15) |
- Citation: Papaconstantinou I, Kapizioni C, Legaki E, Xourgia E, Karamanolis G, Gklavas A, Gazouli M. Association of miR-146 rs2910164, miR-196a rs11614913, miR-221 rs113054794 and miR-224 rs188519172 polymorphisms with anti-TNF treatment response in a Greek population with Crohn’s disease. World J Gastrointest Pharmacol Ther 2017; 8(4): 193-200
- URL: https://www.wjgnet.com/2150-5349/full/v8/i4/193.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v8.i4.193